化浊解毒方治疗慢性萎缩性胃炎伴幽门螺杆菌感染患者的临床研究
Effects of Huazhuo Jiedu Formula on Chronic Atrophic Gastritis Patients with Helicobacter Pylori<\i> Infection
-
摘要: 目的 观察化浊解毒方治疗浊毒内蕴证慢性萎缩性胃炎(CAG)伴幽门螺杆菌感染(Hp)患者的Hp根除率及临床疗效,探讨其可能的作用机制。方法 将120例CAG伴Hp感染患者随机分为治疗组和对照组各60例。治疗组予化浊解毒方口服,每日1剂;对照组先予标准四联杀菌疗法服用2周,继予安慰剂口服,每日1剂。治疗3个月后比较2组治疗前后的中医证候积分、胃镜黏膜征象积分、病理学组织改变积分、胃泌素-17(G-17)、血清胃蛋白酶原Ⅰ、Ⅱ(PGⅠ、PGⅡ)、PGⅠ/PGⅡ比值(PGR)、细胞毒素相关蛋白(CagA)、空泡细胞毒素(VacA)及尿素酶B(UreB)水平变化;治疗前、治疗6周、治疗3个月记录Hp根除率,并随访6个月,观察Hp的复发情况。结果 治疗后,2组中医证候积分均较治疗前降低(P<0.05~0.01),优于对照组(P<0.05~0.01)。治疗组的胃镜黏膜征象积分、病理学组织改变积分均较治疗前降低(P<0.05~0.01),优于对照组(P<0.01)。治疗组PGⅠ、PGR水平较治疗前升高,PGⅡ、G-17水平较治疗前降低(P<0.05~0.01),优于对照组(P<0.05~0.01)。2组CagA、VacA及UreB的阳性率均较治疗前明显降低(P<0.01),优于对照组(P<0.05~0.01)。治疗组Hp根除率优于对照组(P<0.05~0.01)。随访6个月,治疗组复发率低于对照组(P<0.01)。结论 化浊解毒方治疗浊毒内蕴证CAG伴Hp感染,抑杀Hp效果好,复发率低,且可有效缓解临床症状、改善病理组织学病变、促进黏膜修复,其治疗CAG的作用机制可能与影响CagA、VacA、UreB、PGⅠ、PGⅡ、PGR及G-17的水平相关。Abstract: OBJECTIVE To observe the Helicobacter pylori(Hp) eradication rate and clinical effect of Huazhuo Jiedu Formula in the treatment of chronic atrophic gastritis (CAG) with Hp infection, and to explore its possible mechanism. METHODS 120 patients of CAG with Hp infection were randomly divided into two groups: the treatment group and the control group. The treatment group was given one dose of Huazhuo Jiedu formula per day, while the control group was given standard quadruple bactericidal therapy for 2 weeks, followed by placebo, one dose per day. After 3 months' treatment, TCM syndrome score, gastroscope mucosal symptom score, pathological tissue change score, gastrin-17 (G-17), serum pepsinogen Ⅰ, Ⅱ (PGⅠ, PGⅡ), PGⅠ/PG Ⅱ ratio (PGR), cytotoxin associated protein (CagA), vacuole cytotoxin (VacA) and urease B (UreB) of the two groups were compared before and after treatment. The eradication rate of HP was recorded before treatment, 6 weeks and 3 months after treatment, and after the follow-up for 6 months to observe the recurrence of Hp. RESULTS After three months' treatment, TCM syndrome scores in the two groups were significantly lower than those before treatment with significant difference (P<0.05, P<0.01), compared with the control group (P<0.05, P<0.01). Compared with the control group, the gastroscope mucosal symptom score and pathological tissue change score in the treatment group were lower than those before treatment (P<0.05, P<0.01), compared with the control group (P<0.05, P<0.01). The levels of PGⅠ and PGR in the treatment group were higher than those before treatment, and the levels of PG Ⅱ and G-17 were lower than those before treatment (P<0.05, P<0.01), compared with the control group (P<0.05, P<0.01). The positive rates of CagA, VacA and UreB in the two groups were significantly lower than those before treatment (P<0.01), compared with the control group (P<0.05, P<0.01). The eradication rate of Hp of patients in the treatment group was better than that in the control group (P<0.05). The 6 months follow-up recurrence rate of the treatment group was lower than that of the control group (P<0.01). CONCLUSION Huazhuo Jiedu formula, having good effect on Hp inhibition and low recurrence rate, is effective in the treatment of CAG with Hp infection. It can effectively alleviate clinical symptoms, improve pathological changes and promote mucosal repair. Its mechanism may be related to the levels of CagA, VacA, UreB, PGⅠ, PGⅡ, PGR and G-17.
-
[1] 中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131. [2] ASAKA M,SUGIYAMA T,NOBUTA A,et al.Atrophic gastritis and intestinal metaplasia in Japan: Results of a large multicenter study[J].Helicobacter, 2001,6(4) :294-299. [3] VENERITO M,MALFERTHEINER P.Preneoplastic conditions in the stomach: Always a point of no return?[J].Dig Dis,2015,33(1) :5-10. [4] KAZUMASA MIKI. Gastric cancer screening by combined assay for serum anti-helicobacter pylori IgG antibody and serum pepsinogen levels: "ABC method"[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2011, 87(7): 405-414. [5] 杨勇,王翼洲.扶正清热灭幽汤治疗Hp感染慢性浅表性胃炎30例[J].湖南中医杂志,2013,29(12):17-20. [6] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组,全国幽门螺杆菌研究协作组.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学,2017,22(6):346-360. [7] 中华中医药学会脾胃病分会.慢性萎缩性胃炎中医诊疗共识意见[J].中医杂志,2010,51(8):749-753. [8] 中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:124-129. [9] 吴庆和.益气健脾活血法结合艾箱灸治疗脾虚型CAG的临床及实验研究[D].广州:广州中医药大学,2014. [10] WONG BC,LAM SK,WONG WM,et al. Helicobacter pylori<\i> eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial[J]. JAMA,2004, 291(2): 187-194. [11] ZHANG YX, ZHOU LY, SONG ZQ, et al. Primary antibiotic resistance of Helicobacter pylori strains is olated from patients with dyspeptic symptoms in Beijing: A prospective serial study[J]. World J Gastroenterol, 2015,21(9):2786-2792. [12] 恽笑.连蒲饮对慢性胃炎患者幽门螺杆菌及其CagA、VacA蛋白的影响[D].南京:南京中医药大学,2017. [13] 李佃贵.中医浊毒论[M].北京:人民卫生出版社,2016:6-17. [14] SAMLOFF IM. PepsinogensⅠ and Ⅱ: Purification from gastric mucosa and radio immunoassay in serum[J]. Gastroenterology, 1982, 82: 26-33. [15] 王雪华,曹燕,张剑宏,等.血清胃蛋白酶原联合胃泌素测定在胃癌及萎缩性胃炎中的诊断价值[J].中华临床医师杂志,2015,9(10):1824-1827. [16] 熊文坚,陆思源,金惠,等.癌前病变及胃癌的有效血清学筛查方法研究[J].中国临床医学,2006,13(6):953-954. [17] 黄亚娜,唐世孝.胃泌素与胃癌关系的研究进展[J].西南军医,2012,14(5):757-760. [18] CON SA, TAKEUCHI H, CON-CHIN GR, et al.Role of bacterial and genetic factors in gastric cancer in Costa Rica[J].World J Gastroenterol,2009,15(2):211-218. [19] 杨燕,单万水,韩红星,等.免疫印迹法检测幽门螺杆菌抗体及其分型的结果分析[J].检验医学与临床,2013,10(A1):28-30. [20] FERREIRA RM,PINTO-RIBEIRO I,WEN X,et al.Helicobacter pylori<\i> CagA promoter region sequences influence CagA expression and interleukin 8 secretion[J].J Infect Dis,2015,213(4):669-673. [21] WILLHITE DC,BLANKE SR. Helicobacter pylori vacuolating cytotoxin enters cells,localizes to the mitochondria,and induces mitochondrial membrane permeability changes correlated to toxin channel activity[J].Cell Microbiol,2004,6(2):143-154. [22] 刘贤,何帮顺,林康,等.幽门螺杆菌基因分型与胃病关系研究进展[J].现代生物医学进展,2016,16(7):1390-1393.
点击查看大图
计量
- 文章访问数: 520
- HTML全文浏览量: 2
- PDF下载量: 366
- 被引次数: 0